Emerging agents for the treatment of mantle cell lymphoma.

about

Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.

P2860

Q38122437-C11DED90-E934-419F-BA0C-D876ABA087AD

P2860

Emerging agents for the treatment of mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q38055498

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging agents for the treatment of mantle cell lymphoma.

@en

type

Item

label

Emerging agents for the treatment of mantle cell lymphoma.

@en

prefLabel

Emerging agents for the treatment of mantle cell lymphoma.

@en

P1476

Emerging agents for the treatment of mantle cell lymphoma.

@en

P2093

Valérie Camara-Clayette

http://www.w3.org/2001/XMLSchema#string

Vincent Ribrag

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

P304

1205-1215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.12.99

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23098120

http://www.w3.org/2001/XMLSchema#string

Emerging agents for the treatment of mantle cell lymphoma.

about

P2860

P2860

Emerging agents for the treatment of mantle cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698